List of Excipients in Branded Drug MOXIFLOXACIN OPHTHALMIC SOLUTION

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	MOXIFLOXACIN OPHTHALMIC SOLUTION	moxifloxacin hydrochloride	0781-7135	BORIC ACID
Sandoz Inc	MOXIFLOXACIN OPHTHALMIC SOLUTION	moxifloxacin hydrochloride	0781-7135	HYDROCHLORIC ACID
Sandoz Inc	MOXIFLOXACIN OPHTHALMIC SOLUTION	moxifloxacin hydrochloride	0781-7135	SODIUM CHLORIDE
Sandoz Inc	MOXIFLOXACIN OPHTHALMIC SOLUTION	moxifloxacin hydrochloride	0781-7135	SODIUM HYDROXIDE
Sandoz Inc	MOXIFLOXACIN OPHTHALMIC SOLUTION	moxifloxacin hydrochloride	0781-7135	WATER

Generic Drugs Containing MOXIFLOXACIN OPHTHALMIC SOLUTION

Company	Ingredient	NDC	Excipient
Alembic Pharmaceuticals Limited	moxifloxacin ophthalmic solution	46708-505	BORIC ACID
Alembic Pharmaceuticals Limited	moxifloxacin ophthalmic solution	46708-505	HYDROCHLORIC ACID
Alembic Pharmaceuticals Limited	moxifloxacin ophthalmic solution	46708-505	SODIUM CHLORIDE
Alembic Pharmaceuticals Limited	moxifloxacin ophthalmic solution	46708-505	SODIUM HYDROXIDE
Alembic Pharmaceuticals Limited	moxifloxacin ophthalmic solution	46708-505	WATER

What are the Most Frequently-Used Excipients in MOXIFLOXACIN OPHTHALMIC SOLUTION?

# Of NDCs	Excipient
8	BORIC ACID
8	HYDROCHLORIC ACID
8	SODIUM CHLORIDE
8	SODIUM HYDROXIDE
8	WATER

Moxifloxacin Ophthalmic Solution Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Moxifloxacin ophthalmic solution is a mature generic ophthalmic antibiotic market in which commercial differentiation depends more on preservative profile, dosing convenience, container design, and supply reliability than on the active ingredient. The core opportunity is a preservative-free or low-irritancy multidose product, supported by validated sterility, ocular-surface tolerability, and a clear substitution strategy against branded and generic moxifloxacin products.

What is the excipient composition of moxifloxacin ophthalmic solution?

Moxifloxacin ophthalmic solution is typically formulated at 0.5% moxifloxacin, equivalent to 5 mg/mL of moxifloxacin base. The commercial excipient architecture differs by product.

Product	Active ingredient	Key excipients	Preservative status	Typical dosing
Vigamox	Moxifloxacin hydrochloride 0.5%	Boric acid, sodium chloride, benzalkonium chloride, purified water; pH adjustment with hydrochloric acid or sodium hydroxide	Preserved with benzalkonium chloride at 0.005%	One drop three times daily for seven days
Moxeza	Moxifloxacin hydrochloride 0.5%	Boric acid, sodium chloride, sorbitol, purified water; pH adjustment as needed	No benzalkonium chloride listed in the U.S. label	One drop twice daily for seven days
Generic products	Moxifloxacin hydrochloride 0.5%	Varies by ANDA sponsor; commonly includes boric acid, sodium chloride, purified water, and either a preservative or preservative-free presentation	Product-specific	Commonly three times daily, depending on labeling

Sources: FDA Vigamox prescribing information; FDA Moxeza prescribing information; DailyMed product labels.[1-3]

The principal formulation choices are:

1. Whether to use benzalkonium chloride or another antimicrobial preservative.
2. Whether to include a viscosity modifier or solubilizing excipient.
3. Whether to use a borate buffer system.
4. Whether to commercialize in a multidose bottle, unit-dose container, or both.
5. Whether to optimize for standard generic substitution or a differentiated ophthalmology product.

Which excipients are most important in moxifloxacin ophthalmic formulation?

Benzalkonium chloride

Benzalkonium chloride, or BAK, is used to maintain multidose container sterility. It is effective at low concentrations and has extensive precedent in ophthalmic products. Its commercial disadvantage is potential ocular-surface irritation, particularly with repeated exposure, compromised corneas, dry-eye disease, postoperative use, or chronic concomitant therapy.

For an acute seven-day antibiotic course, BAK exposure is limited compared with chronic glaucoma treatment. That reduces, but does not eliminate, the commercial rationale for a preservative-free alternative. A BAK-containing product remains the lowest-complexity route for a conventional generic multidose bottle.

Boric acid and sodium chloride

Boric acid and sodium chloride support buffering and tonicity. They are familiar ophthalmic excipients with established regulatory precedent. A borate system can help maintain a target pH while minimizing discomfort at instillation.

The formulation target should balance:

• Chemical stability of moxifloxacin.
• Ocular comfort.
• Isotonicity or near-isotonicity.
• Compatibility with the bottle and closure.
• Robustness during sterilization and shelf storage.

Sorbitol

Sorbitol is used in the Moxeza formulation and can contribute to tonicity and product feel. It provides a route to an unpreserved formulation without relying on BAK for the product’s commercial positioning. Sorbitol concentration must be controlled because excessive osmotic load can affect comfort and tolerability.

Viscosity modifiers

Viscosity modifiers such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, povidone, carbomers, or xanthan gum can extend ocular residence time. They may support less frequent dosing or reduce drainage through the nasolacrimal system.

The tradeoff is material:

• Higher viscosity may improve retention.
• Excessive viscosity can cause blurred vision.
• Polymer systems can complicate filtration, filling, and drop-size control.
• Polymer-excipient combinations may create greater formulation and patent exposure than a simple aqueous solution.
• A viscosity-enhanced product may no longer be a straightforward bioequivalent generic pathway if the formulation materially changes delivery behavior.

A commercial sponsor should not add a viscosity modifier without a defined clinical or user benefit. In a mature antibiotic market, unnecessary formulation complexity increases cost and regulatory risk.

What is the best preservative strategy for commercial moxifloxacin eye drops?

The strongest commercial strategy is usually a two-tier portfolio:

Product	Target customer	Commercial role	Main advantage	Main risk
Preserved multidose bottle	Retail pharmacy, managed care, routine conjunctivitis	Low-cost volume product	Simple manufacturing and established use	Limited differentiation and BAK concerns
Preservative-free multidose bottle	Ophthalmologists, postoperative patients, ocular-surface-sensitive users	Premium or differentiated product	Lower preservative exposure and improved positioning	More complex sterility and container-closure validation
Preservative-free unit-dose	Hospitals, surgery centers, pediatric and high-risk patients	Institutional and specialty product	No in-use preservative exposure	Higher packaging and distribution cost
Viscosity-enhanced product	Specialty ophthalmology	Differentiated line extension	Potentially longer residence time or reduced dosing frequency	Greater regulatory and development burden

A preserved product has the clearest route to ANDA approval and broad pharmacy distribution. A preservative-free product has the better differentiation profile but requires a stronger container-closure and in-use microbiological package.

The practical opportunity is not simply to remove BAK. The product must demonstrate acceptable sterility maintenance after repeated opening, controlled drop size, low sorption of moxifloxacin to packaging, and acceptable use through the labeled in-use period.

How can a preservative-free moxifloxacin solution be commercialized?

Preservative-free multidose packaging

A preservative-free multidose bottle requires a delivery system that limits microbial ingress or meters sterile product without conventional preservatives. Available approaches include:

• One-way valves.
• Airless multidose containers.
• Sterile-filtered or sterile-manufactured barrier systems.
• Proprietary dispensing pumps.
• Collapsible or non-return bottle designs.

The product’s differentiation would arise from the combination of active ingredient, aqueous formulation, and container-closure system. The container system may be the principal intellectual-property asset.

The regulatory burden includes:

• Sterility testing.
• Container-closure integrity.
• Microbial ingress or simulated-use testing.
• In-use stability.
• Drop-size consistency.
• Extractables and leachables.
• Compatibility with terminal sterilization or aseptic processing.
• Human-factors assessment where the device is nonconventional.

Preservative-free unit-dose packaging

Unit-dose packaging is technically simpler from a microbial-use perspective. It is suitable for surgical centers, hospital formularies, and patients who should avoid preservative exposure. Its disadvantages are higher packaging cost, more units per treatment course, greater package volume, and potential waste when treatment ends before all units are used.

Unit-dose products can compete where the purchasing decision is driven by ocular-surface tolerability, infection-control policy, or postoperative protocols rather than lowest acquisition cost.

What formulations are protected by moxifloxacin ophthalmic patents?

Moxifloxacin ophthalmic products can involve several distinct intellectual-property layers:

IP layer	Typical subject matter	Commercial relevance
Active ingredient	Moxifloxacin compound and salts	Core compound protection is generally no longer the main barrier for ophthalmic generics
Ophthalmic composition	Concentration, pH, buffer, tonicity, preservative, or polymer combinations	May affect freedom to operate for differentiated formulations
Method of use	Treatment of bacterial conjunctivitis, keratitis, or prophylaxis	Usually relevant only where claims remain enforceable and are listed or asserted
Container system	Preservative-free multidose dispensing, valve, pump, or barrier technology	Can create the strongest current barrier for premium presentations
Manufacturing process	Sterile filtration, aseptic filling, crystallization, impurity control, or packaging	Relevant to supply reliability and process differentiation
Regulatory exclusivity	NDA exclusivity or pediatric exclusivity	May delay or limit certain generic approvals

The original Vigamox and Moxeza products are mature FDA-approved products. The principal commercial issue is therefore not basic moxifloxacin compound exclusivity but the patent position around specific formulations, delivery systems, and product-specific claims. Patent status must be assessed in the current FDA Orange Book, USPTO records, and litigation databases for the intended presentation.[4-6]

Are there formulation-patent opportunities?

Yes. The strongest opportunities are likely to involve:

• Preservative-free multidose delivery.
• Controlled drop size and reduced wastage.
• Low-irritancy aqueous systems.
• Enhanced ocular residence without visual blurring.
• Packaging that reduces microbial ingress.
• Improved stability under temperature excursions.
• Formulations compatible with postoperative ocular tissues.
• Combination products using moxifloxacin with another ophthalmic active ingredient.

A patent application directed only to moxifloxacin, water, sodium chloride, and boric acid is likely to face substantial novelty and obviousness pressure because similar compositions have long regulatory precedent. Stronger claims would require a defined technical effect, unusual excipient range, measurable stability benefit, improved tolerability, or a specialized container system.

When does moxifloxacin ophthalmic solution lose exclusivity?

Moxifloxacin ophthalmic solution is already exposed to generic competition in the United States. Vigamox was approved in 2003, and Moxeza was approved in 2010.[1,2] The market has passed the period in which basic NDA exclusivity would be the primary commercial protection.

Milestone	Vigamox	Moxeza
FDA approval	2003	2010
Dosage form	0.5% ophthalmic solution	0.5% ophthalmic solution
Original commercial protection	Compound, formulation, and regulatory protections	Product-specific formulation and regulatory protections
Current market posture	Mature branded and generic market	Mature branded and generic market
Main remaining barriers	Product-specific patents, device claims, contracting, supply	Product-specific patents, device claims, contracting, supply

Because the products are mature, a new entrant should model commercial success around cost, channel access, product differentiation, and manufacturing quality rather than reliance on broad exclusivity.

What is the Orange Book status of moxifloxacin ophthalmic solution?

The Orange Book identifies FDA-approved drug products and, where applicable, patents and exclusivity associated with listed products. Moxifloxacin ophthalmic solution products should be reviewed by NDA number, applicant, dosage form, and active ingredient rather than by brand name alone.[4]

For a conventional generic 0.5% solution, the relevant regulatory route is generally an ANDA referencing the listed drug. The applicant must demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable FDA requirements for ophthalmic solutions. A materially different preservative-free container system, dosage regimen, or delivery technology may require a 505(b)(2) strategy or additional clinical and device-related evidence, depending on the product design.

Which companies are challenging or competing with branded moxifloxacin?

Competition includes:

• Generic ophthalmic manufacturers selling moxifloxacin 0.5%.
• Branded and authorized-generic suppliers.
• Manufacturers of other topical fluoroquinolones.
• Combination ophthalmic products containing moxifloxacin and a corticosteroid.
• Products using gatifloxacin, ofloxacin, ciprofloxacin, or besifloxacin.
• Hospitals and surgery centers purchasing preservative-free unit-dose antibiotics.

The most relevant competitive comparison is not limited to antibiotic spectrum. Buyers also assess acquisition cost, dosing frequency, preservative profile, bottle performance, availability, and formulary contracting.

Competitive attribute	Standard generic moxifloxacin	Differentiated moxifloxacin	Besifloxacin or other branded antibiotic
Active ingredient familiarity	High	High	Variable
Price pressure	Very high	Moderate to high	Higher
Preservative-free potential	Product-specific	Core opportunity	Product-specific
Dosing differentiation	Limited	Possible through formulation	Product-specific
Switching friction	Low for routine cases	Moderate	Higher when brand preference exists
Contracting leverage	Scale-driven	Quality and clinical-value driven	Brand and specialty driven

What generic launch risks exist for moxifloxacin ophthalmic solution?

Price erosion

The conventional 0.5% solution is vulnerable to rapid price compression once several ANDA suppliers are active. A new sponsor needs a manufacturing-cost advantage, a reliable supply record, or differentiated packaging to avoid competing only on price.

Product substitution

Pharmacy substitution favors products that match the reference product in concentration, dosage form, bottle size, labeling, and preservative profile. A preservative-free product may attract specialist prescribing but may not receive automatic substitution in every commercial setting.

Sterility and recall exposure

Ophthalmic products carry high recall sensitivity because microbial contamination can cause serious ocular injury. The main manufacturing risks are:

• Aseptic-processing failure.
• Weak environmental monitoring.
• Container-closure defects.
• Inconsistent fill volumes.
• Tip contamination during use.
• Particulates or visible foreign matter.
• Inadequate preservative effectiveness where a preservative is used.

FDA warning letters and ophthalmic recalls show that manufacturing controls can materially affect a product’s commercial position even when the active ingredient is commoditized.[7]

Labeling and use errors

Nonstandard packaging can create administration errors. Unit-dose presentations can be confused with injectable products or discarded after partial use. Multidose preservative-free bottles require clear instructions and robust user testing.

How strong is the patent estate for a new moxifloxacin ophthalmic product?

The patent strength depends on the product architecture.

Product architecture	Patent strength	FTO risk	Commercial defensibility
Conventional BAK-preserved 0.5% solution	Low	Low to moderate	Low
Conventional preservative-free unit-dose	Moderate	Moderate	Moderate
Preservative-free multidose with proprietary valve	Moderate to high	High around device claims	High if performance is validated
Viscosity-enhanced formulation	Moderate	Moderate to high	Moderate
Moxifloxacin combination product	Moderate to high	Active-ingredient and method claims	High, subject to clinical and IP review
New manufacturing process	Moderate	Process-specific	Moderate if it lowers cost or improves impurities

The strongest strategy is to claim the formulation and dispensing system together where the delivery system produces a measurable result. Claims should be supported by microbial ingress data, stability data, dose uniformity, and ocular tolerability evidence.

What licensing deals and partnerships could support market entry?

Publicly disclosed licensing opportunities in generic moxifloxacin are likely to be less important than technology and channel partnerships. The most commercially relevant structures are:

• Licensing a preservative-free multidose container.
• Contract manufacturing with an FDA-inspected ophthalmic facility.
• Co-development with an ophthalmology company that has specialist sales coverage.
• Supply agreements with hospital and ambulatory surgery-center distributors.
• Authorized-generic arrangements with a branded pharmaceutical company.
• Regional licensing for markets requiring local registration or local manufacturing.

The value of a license depends on whether the technology solves a real market problem. A dispensing system that supports a credible preservative-free claim is more defensible than a license covering routine buffer and tonicity excipients.

How can moxifloxacin ophthalmic solution generate commercial value?

U.S. retail generic

This is the volume opportunity but also the most price-sensitive segment. Success requires:

• Low-cost sterile manufacturing.
• Multiple bottle sizes.
• Consistent pharmacy supply.
• Wholesaler and group-purchasing access.
• Competitive contract pricing.
• Low complaint and recall rates.

Hospital and surgical-center supply

Preservative-free unit-dose products can command a stronger position in hospitals and surgery centers where infection control, postoperative use, and ocular-surface tolerability influence procurement.

Specialty ophthalmology

A preservative-free or low-irritancy product can be positioned for patients with dry eye, corneal disease, repeated topical therapy, or postoperative sensitivity. The commercial claim must remain consistent with the product label and supported by appropriate evidence.

Emerging markets

Geographic opportunities exist where branded moxifloxacin remains expensive, generic penetration is incomplete, or local ophthalmic manufacturing is limited. Regulatory requirements vary by jurisdiction, especially for preservative-free multidose packaging, sterile manufacturing, and combination products.

Veterinary ophthalmology

Moxifloxacin is used in veterinary ophthalmic practice, but veterinary commercialization requires separate regulatory, labeling, distribution, and promotional analysis. Human ophthalmic approval does not automatically establish a veterinary product opportunity.

What manufacturing and IP barriers affect moxifloxacin eye drops?

The principal manufacturing barriers are sterile aqueous processing, microbial-control validation, bottle performance, and long-term stability. The active ingredient itself is readily understood, but the finished product must control:

• Assay and degradation products.
• pH and osmolarity.
• Visible and subvisible particulates.
• Drop weight and delivery consistency.
• Container-closure integrity.
• Preservative concentration, when applicable.
• Compatibility between moxifloxacin and plastic, elastomer, and closure materials.

The principal IP barriers are likely to arise from specialized packaging, preservative-free multidose systems, viscosity-enhanced delivery, and combination products. A sponsor should conduct a claim-by-claim freedom-to-operate review before selecting the commercial presentation.

Key Takeaways

• Moxifloxacin ophthalmic solution is a mature generic market with limited value in an undifferentiated conventional formulation.
• BAK-preserved multidose products offer the simplest regulatory and manufacturing route but have limited premium potential.
• Preservative-free multidose delivery is the strongest formulation and commercial opportunity.
• Unit-dose packaging fits hospitals, surgery centers, postoperative care, and ocular-surface-sensitive patients but carries higher packaging cost.
• Boric acid, sodium chloride, sorbitol, and purified water have established ophthalmic precedent.
• Viscosity modifiers should be used only where retention, dosing, or comfort benefits are demonstrated.
• Patent value is more likely to reside in the container-closure system and formulation-performance combination than in the moxifloxacin active ingredient.
• Generic launch economics depend on sterile manufacturing scale, channel access, supply reliability, and product differentiation.
• A two-product portfolio, consisting of a low-cost preserved multidose generic and a preservative-free premium presentation, offers the broadest commercial coverage.

FAQs About Moxifloxacin Ophthalmic Solution Excipient Strategy

Is benzalkonium chloride necessary in moxifloxacin eye drops?

No. BAK is used in some multidose products, including Vigamox, but Moxeza is labeled without BAK. Preservative-free products require suitable packaging and validated microbial-control performance.

Can sorbitol replace benzalkonium chloride?

No. Sorbitol can support tonicity and formulation design, but it is not a conventional antimicrobial preservative. A preservative-free product needs a container and manufacturing strategy that controls microbial contamination.

Is a preservative-free moxifloxacin product automatically eligible for ANDA approval?

Not necessarily. The active solution may be suitable for an ANDA, but a materially different container system, dosing profile, or delivery technology can create additional regulatory requirements.

Which moxifloxacin eye-drop presentation has the highest commercial margin potential?

A preservative-free multidose product generally has greater differentiation and margin potential than a standard preserved generic, provided the dispensing system is reliable and the added packaging cost is controlled.

Are moxifloxacin formulation patents still the main barrier to generic entry?

Usually no for conventional 0.5% solutions. Current barriers are more likely to involve product-specific formulation claims, delivery-device patents, combination products, manufacturing processes, and commercial contracting.

References

1. U.S. Food and Drug Administration. (2003). Vigamox (moxifloxacin hydrochloride ophthalmic solution) prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda/

2. U.S. Food and Drug Administration. (2010). Moxeza (moxifloxacin hydrochloride ophthalmic solution) prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda/

3. National Library of Medicine. (n.d.). DailyMed: Moxifloxacin ophthalmic solution product labeling. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

6. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

7. U.S. Food and Drug Administration. (n.d.). Drug safety communications, recalls, warning letters, and ophthalmic drug manufacturing guidance. https://www.fda.gov/drugs/recalls; https://www.fda.gov/drugs/pharmaceutical-quality-resources/drug-manufacturing-and-quality/ophthalmic-drug-productsnts